Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, elaborates on the scope of unmet need for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and how the treatment landscape is evolving

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic renal cell carcinoma (mRCC) who may be treated with combination I-O in the front line setting

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various TKIs available for renal cell cancer (RCC) patients

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, shares outcomes of the study presented at the 2019 Genitourinary Cancers Symposium using a tumor-specific radioligand - LuPSMA – in men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard therapies

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of a GU 2019 Phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC) are practice changing

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, considers how prostate-specific antigen (PSA) is most valuable as a biomarker in the treatment of prostate cancer

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the TIVO-3 study investigating tivozanib in highly refractory advanced renal cell carcinoma (RCC)

Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, discusses some of the present challenges with using biomarkers for treatment selection in muscle-invasive and non-muscle-invasive bladder cancer

Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, shares results from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)

Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, tells us about the results of CHECKMATE 650 and the potential to use immune checkpoint inhibitor combinations to treat metastatic castration-resistant prostate cancer (mCRPC)

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, shares thoughts on the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)

Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, elaborates on outcomes from the KEYNOTE 057 trial investigating pembrolizumab in patients with high-risk non-muscle-invasive bladder cancer unresponsive to BCG

Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, regarding the outcomes of the Phase 2 STREAM study investigating enzalutamide plus salvage radiation plus androgen deprivation therapy (ADT) in men with pre-metastatic prostate cancer

Dr. Lotan, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, explains how checkpoint inhibition is being incorporated into muscle-invasive and non-muscle-invasive bladder cancer treatment algorithms and whether it appears to combine well with chemotherapy

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, discusses combining checkpoint inhibition or any I-O with TKIs in renal cell cancer patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares outcomes of the KEYNOTE 426 Phase III study investigating pembrolizumab combined with axitinib versus standard of care sunitinib as first line therapy for metastatic renal cell carcinoma (mRCC)

Dr. Armstrong, Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, elaborates on his experience with androgen receptor inhibitors and how they may impact bone scans

Dr. Oh, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, summarizes the large retrospective trial presented the 2019 Genitourinary Cancers Symposium demonstrating that African-American men may respond well to newer prostate cancer therapies

Dr. Fleming, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, regarding outcomes from the ARCHES trial presented at the 2019 Genitourinary Cancers Symposium investigating androgen deprivation therapy (ADT) with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer (mHSPC)

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, on whether the results of KEYNOTE-426 and CHECKMATE 214 influence how we treat intermediate/poor risk renal cell cancer (RCC) patients versus those that are favorable risk in the first line setting